Status:
COMPLETED
Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma
Lead Sponsor:
Spectrum Pharmaceuticals, Inc
Conditions:
Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL su...
Eligibility Criteria
Inclusion
- Relapsed or Refractory mantle cell lymphoma and/or CLL/SLL except Burkitt's, Burkitt's like or HIV-associated lymphoma
- at least one prior cytotoxic chemotherapy regimens
- measurable disease
- adequate bone marrow, liver and kidney function
- ECOG PS 0-2
Exclusion
- prior treatment with elsamitrucin
- prior chemo, antibody or radiotherapy for NHL within 28 days prior to start to treatment
- HIV positive or known AIDS syndrome
- uncontrolled medical disease or psychiatric condition/s
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT00090090
Start Date
April 1 2004
End Date
October 1 2006
Last Update
January 15 2008
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Alta Bates Cancer Center
Berkeley, California, United States, 94704
2
Providence Saint Joseph Medical Center
Burbank, California, United States, 91505
3
USC Norris Cancer Center
Los Angeles, California, United States, 90033
4
Tower Hematology Oncology Medical Group
Los Angeles, California, United States, 90048